Board of Directors

team_nassim2

Nassim Usman, Ph.D. – Venture Partner, Morgenthaler Ventures

Dr. Usman joined Morgenthaler Ventures as Entrepreneur-in-Residence in 2005 and is now a Venture Partner. He is also Chief Executive Officer and a member of the Board of Directors of Catalyst Biosciences. Prior to joining Morgenthaler, he was Senior Vice President and Chief Operating Officer at Sirna (RNAI) Therapeutics Inc., which was acquired by Merck (MRK) in 2006. He held various R&D positions at both Sirna and Ribozyme Pharmaceuticals (RZYM), including Vice President of R&D and Chief Scientific Officer. Dr. Usman also serves on the Boards of Mosaic Biosciences and Osprey Pharmaceuticals, is a past director of Archemix Corporation and atugen AG (now Silence Therapeutics [SLN]) and served on the scientific advisory boards of RXi Pharmaceuticals and Noxxon Pharma AG. He received a Ph.D. degree in Organic Chemistry from McGill University.

team_mark

Mark Lupa, Ph.D. – Managing Director of High Country Ventures

With a Masters in Bioengineering and a PhD in Pharmacology, Dr. Lupa has a unique pedigree that includes 15 years medical research experience and being a Founder, former CEO, and CFO of Tabernash Brewing Company.  In addition to his work with Mosaic Mark serves on several boards, including LeftHand/Tabernash, Oberon, TheraTogs, Surefire Medical, and Endoshape.

Gus Lawlor – Managing Director of HealthCare Ventures

Gus Lawlor has been a Managing Director of HealthCare Ventures since 2000.  He was previously Chief Operating Officer of LeukoSite, Inc., a HealthCare Ventures III, IV, and V company.  Before joining LeukoSite, he was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technology.  He held similar positions at BioSurface Technology and Armstrong Pharmaceuticals.  He received a Master’s degree in Public and Private Management from Yale University.

team_marty2

Marty Stanton, Ph.D. – CEO of Mosaic Biosciences